Biogen has announced a $2 billion investment to upgrade and expand its North Carolina operations, emphasizing automation and artificial intelligence in its manufacturing capabilities. The move solidifies its role as the largest biotechnology employer in the state and positions the company for future pharmaceutical innovation.
Founded in 1995 in Research Triangle Park, Biogen now employs more than 1,500 people and 400 contractors across Wake and Durham counties. The company plans to modernize its facilities by expanding antisense oligonucleotide infrastructure and establishing new clinical and commercial fill-finish capabilities.
According to company financials, Biogen generated $9.68 billion in revenue in 2024, with a net income of $1.63 billion and a profit margin of 17 percent. About 90 percent of its commercial medicines are manufactured and tested in the United States.
Nicole Murphy, head of Biogen’s Pharmaceutical Operations and Technology, said the investment aims to reinforce the company’s drug development pipeline while supporting North Carolina’s skilled life sciences workforce. The facilities upgrade will help ensure resilient supply chains and enable production for future therapies.
Unlike other recent corporate expansions in the state, Biogen’s announcement does not include new taxpayer-funded incentives. The company has previously received state-level grants, tax credits, and training support, but this investment proceeds independently.
Rep. Pat Harrigan (R-NC) credited the expansion to the pro-business policies of President Donald Trump, citing tax cuts, deregulation, and supply chain reforms as critical drivers in revitalizing American manufacturing.
Biogen’s announcement follows a wave of major corporate investments in North Carolina, including JetZero’s $4.7 billion commitment in the Triad, Amazon Web Services’ $10 billion in Richmond County, and Jabil’s $500 million in Rowan County—all of which involved state and local incentives.
